Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3D Global Biotech's Days Sales Outstanding for the
six
months ended in Dec. 2025 was 84.06.
3D Global Biotech's Days Inventory for the
six
months ended in Dec. 2025 was 138.34.
3D Global Biotech's Days Payable for the
six
months ended in Dec. 2025 was 9.07.
Therefore, 3D Global Biotech's Cash Conversion Cycle (CCC) for the
six
months ended in Dec. 2025 was 213.33.
3D Global Biotech (ROCO:6808) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
3D Global Biotech Cash Conversion Cycle Related Terms
3D Global Biotech Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for 3D Global Biotech's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6808 vs VRTX, REGN, ALNY: Cash Conversion Cycle Comparison
For the Biotechnology subindustry, 3D Global Biotech's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
3D Global Biotech Cash Conversion Cycle vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 3D Global Biotech's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where 3D Global Biotech's Cash Conversion Cycle falls into.
3D Global Biotech Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
3D Global Biotech's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
3D Global Biotech (ROCO:6808) has a Cash Conversion Cycle of 213.33 as of Dec. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on 3D Global Biotech and its competitors.
Is 3D Global Biotech's Cash Conversion Cycle too high?
3D Global Biotech's current Cash Conversion Cycle is 213.33. The Biotechnology industry median Cash Conversion Cycle is 103.69. 3D Global Biotech's value of 213.33 is 105.7% above this industry median. Overall, 3D Global Biotech has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does 3D Global Biotech's Cash Conversion Cycle compare to VRTX and REGN?
3D Global Biotech's Cash Conversion Cycle of 213.33 can be compared against companies in the Biotechnology industry. The industry median Cash Conversion Cycle is 103.69. 3D Global Biotech's value of 213.33 is 105.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Biotechnology company?
The median Cash Conversion Cycle among Biotechnology companies is 103.69, based on 867 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 3D Global Biotech's current Cash Conversion Cycle of 213.33 is 105.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on 3D Global Biotech and its competitors. For the Biotechnology industry, the median Cash Conversion Cycle is 103.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 3D Global Biotech's current Cash Conversion Cycle is 213.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 3D Global Biotech stock overvalued right now?
Based on GuruFocus' analysis, 3D Global Biotech (ROCO:6808) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$185.91, compared to a current price of NT$38.85 — trading 79.1% below its estimated fair value. The current Cash Conversion Cycle is 213.33 and 105.7% above the Biotechnology industry median of 103.69. 3D Global Biotech's overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For 3D Global Biotech (ROCO:6808), the current Cash Conversion Cycle is 213.33 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 3D Global Biotech (ROCO:6808) Overvalued in 2026?
Based on GuruFocus' analysis, 3D Global Biotech stock appears to be undervalued.
The current stock price of NT$38.85 is trading 79.1% below its estimated GF Value™ of NT$185.91.
GuruFocus considers 3D Global Biotech to be Significantly Undervalued.
Key valuation signals for ROCO:6808:
Cash Conversion Cycle: 213.33
GF Value™: NT$185.91 vs. price of NT$38.85 (79.1% below fair value)
Industry Position: 105.7% above the Biotechnology median
No single metric tells the full story. See the ROCO:6808 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
3D Global Biotech Inc is engaged in the research and development of high-end medical equipment and biological 3D printing technology and the sale of medical Materials and other related products.
70GF Score
Get the complete analysis for ROCO:6808
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6808 has been successfully added to your 
